# Tdap Vaccine in Post-Partum Women

> **NCT01711645** · PHASE4 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 55 (actual)

## Conditions studied

- Diphtheria
- Pertussis
- Tetanus

## Interventions

- **BIOLOGICAL:** Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate

## Key facts

- **NCT ID:** NCT01711645
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-26
- **Primary completion:** 2015-08-28
- **Final completion:** 2015-08-28
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711645, "Tdap Vaccine in Post-Partum Women". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01711645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*